<DOC>
	<DOCNO>NCT02831686</DOCNO>
	<brief_summary>The purpose study test safety combination study drug call selinexor ( KPT-330 ) ixazomib ( MLN9708 ) low dose dexamethasone . This study test different dos study drug , selinexor see dose safe people . Depending group ( dose level ) , dose selinexor vary , ixazomib dexamethasone dos among group .</brief_summary>
	<brief_title>A Study Test Combination Selinexor ( KPT-330 ) , Ixazomib , Dexamethasone Patients With Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>MSKCC confirm diagnosis multiple myeloma relapse resistant therapy least one immunomodulatory drug ( i.e . lenalidomide , thalidomide ) least one proteasome inhibitor . Measurable multiple myeloma disease , define meeting least 1 follow criterion within 14 day prior registration : A monoclonal Ig ( Mprotein ) concentration serum protein electrophoresis ( SPEP ) ≥ 0.5 g/dL . Measurable urinary light chain secretion quantitative analysis use urine protein electrophoresis ( UPEP ) ≥ 200 mg/24 hour . Involved serum free light chain ( FLC ) level ≥ 10 mg/dL , provide serum FLC ratio abnormal . Presence extramedullary plasmacytoma . Patient must ≥ 18 year age time informed consent . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 within 14 day prior registration . Adequate hematology laboratory value within 14 day prior registration : Neutrophils ≥ 1.0 × 10^9/L ( growth factor support allow ) . Platelet count ≥75x10^9/L . In patient significant bone marrow plasmacytosis ( &gt; /=30 % ) platelet count 50 acceptable study entry . Platelet support permit within 14 day although platelet transfusion help participant meet eligibility criterion allow within 72 hour ( 3 day ) prior blood sample confirm protocol eligibility . Adequate hepatic renal function laboratory value within 14 day prior registration : Aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) ≤ 3 × upper limit normal ( ULN ) . Total bilirubin ≤ 1.5 mg/dL except patient history elevate total bilirubin , Gilbert 's . Calculated ( Cockcroft Gault formula ) measure creatinine clearance ≥ 30mL/min . Left ventricular ejection fraction ( LVEF ) ≥ 40 % within 28 day prior registration , evaluate 2D transthoracic echocardiogram ( ECHO ) , ECHO available , multigated acquisition ( MUGA ) scan . Female patient : Are postmenopausal least 1 year screen visit , OR Are surgically sterile , OR If childbearing potential , agree practice 2 effective method contraception , time , time signing informed consent form 90 day last dose study drug , OR Agree practice true abstinence line prefer usual lifestyle subject . ( Periodic abstinence [ e.g. , calendar , ovulation , symptothermal , postovulation method ] withdrawal acceptable method contraception . ) If patient female childbearing potential , must negative serum beta human chorionic gonadotropin ( βHCG ) test within 14 day prior registration consent ongoing pregnancy test course study . Male patient , even surgically sterilize ( i.e. , status postvasectomy ) , must agree one following : Agree practice effective barrier contraception entire study treatment period 90 day last dose study drug , OR Agree practice true abstinence line prefer usual lifestyle subject . ( Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ] withdrawal acceptable method contraception . ) For male female patient , effective method contraception must use throughout study 3 month follow last dose study treatment . Willingness ability comply schedule visit , treatment plan , laboratory test study procedure . Written inform consent accordance federal , local , institutional guideline . The patient must provide informed consent prior first screening procedure . Female patient lactate positive serum pregnancy test screening period . Failure fully recover reversible effect prior anticancer therapy . Major surgery within 14 day prior first dose study drug . Radiotherapy within 14 day prior first dose study drug . If involved field small , 7 day consider sufficient interval treatment administration first dose study medication . Diseaserelated central nervous system involvement . The subject uncontrolled significant intercurrent illness include , limited , ongoing active infection , uncontrolled congestive heart failure , unstable angina pectoris within 6 month , stroke within 6 month , myocardial infarction within 6 month , uncontrolled cardiac arrhythmia , uncontrolled hypertension . Active hepatitis B C virus infection , know human immunodeficiency virus ( HIV ) positive . Any serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol . Known allergy study medication , analogue , excipients various formulation agent . Known GI disease GI procedure could interfere oral absorption study medication include difficulty swallowing . Concurrent malignancy except treated nonmelanoma skin cancer , cervical carcinoma situ lowrisk prostate CA monitor without treatment . Patient Grade 3 peripheral neuropathy Grade 2 pain clinical examination screen period . Chemotherapy within 14 day start trial . Prior exposure SINE compound . Patients unwilling comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Selinexor ( KPT-330 )</keyword>
	<keyword>Ixazomib</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>15-310</keyword>
</DOC>